COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery

Sunny Kumar; Malini Basu; Pratyasha Ghosh; Uttam Pal; Mrinal K. Ghosh

doi:10.1016/j.gendis.2022.12.019

您当前的位置：

首页 >

文章列表页 >

COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery

Review article | 更新时间：2023-08-29

- COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery
- COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery
- Genes & Diseases 2023年10卷第4期
- 作者机构：
  
  1. Department of Economics, Bethune College, University of Calcutta, Kolkata,India,700006
  2. Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology (CSIR-IICB), TRUE Campus, CN-6, Sector–V, Salt Lake, Kolkata-700091 & 4, Raja S.C. Mullick Road, Jadavpur, Kolkata,India,700032
  3. Department of Microbiology, Dhruba Chand Halder College, Dakshin Barasat, West Bengal,India,743372
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.12.019
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-7-1，
扫描看全文
Sunny Kumar, Malini Basu, Pratyasha Ghosh, 等. COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery[J]. Genes & Diseases, 2023,10(4).

Sunny Kumar, Malini Basu, Pratyasha Ghosh, et al. COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery[J]. Genes & Diseases, 2023,10(4).
Sunny Kumar, Malini Basu, Pratyasha Ghosh, 等. COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery[J]. Genes & Diseases, 2023,10(4). DOI： 10.1016/j.gendis.2022.12.019.

Sunny Kumar, Malini Basu, Pratyasha Ghosh, et al. COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery[J]. Genes & Diseases, 2023,10(4). DOI： 10.1016/j.gendis.2022.12.019.

摘要

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes the complicated disease COVID-19. Clinicians are continuously facing huge problems in the treatment of patients

as COVID-19-specific drugs are not available

hence the principle of drug repurposing serves as a one-and-only hope. Globally

the repurposing of many drugs is underway; few of them are already approved by the regulatory bodies for their clinical use and most of them are in different phases of clinical trials. Here in this review

our main aim is to discuss in detail the up-to-date information on the target-based pharmacological classification of repurposed drugs

the potential mechanism of actions

and the current clinical trial status of various drugs which are under repurposing since early 2020. At last

we briefly proposed the probable pharmacological and therapeutic drug targets that may be preferred as a futuristic drug discovery approach in the development of effective medicines.

关键词

Keywords

Clinical trialsCOVID-19Drug discoveryPharmacologyRepurposing of drugsSARS-Cov-2

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment

Single-cell transcriptome landscape and antigen receptor dynamic during SARS-CoV-2 vaccination

Pandemic COVID-19: Current status and challenges of antiviral therapies

Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome

The clinical and immunological features of pediatric COVID-19 patients in China